Transdermal patch and method for augmenting adhesive strength thereof

An adhesive and adhesive technology, applied in pharmaceutical formulations, drug combinations, organic active ingredients, etc., can solve problems such as insufficient adhesion and achieve the effect of enhancing adhesion

Active Publication Date: 2013-06-12
HISAMITSU PHARM CO INC
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in the transdermal patch described in Patent Document 1, the Transdermal Therapeutic System (TTS) described in Patent Document 2, and the device described in Patent Document 3, as a patch that is usually continuously attached to the skin for a long time, Adhesive, the adhesion is not enough

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0069] First, add tolterodine tartrate (0.9g), sodium hydroxide (0.15g: 2-fold molar equivalent to tolterodine tartrate), and tolterodine acetate (0.026g) to an acrylic adhesive (4.97g: "DURO-TAK4287", the Henkel company make) ethyl acetate solution (solid content concentration: 40 mass %), and the adhesive agent layer composition was obtained.

[0070] Next, the obtained adhesive layer composition was coated on a PET (Polyethylene Terephthalate, polyethylene terephthalate) film (“Scotchpack 9732”, manufactured by 3M Company) in a thickness of 100 μm to form an adhesive layer , so as to obtain tolterodine tartrate 3mg / cm 2 (30% by mass in the adhesive layer), tolterodine acetate 0.085 mg / cm 2 (0.85% by mass in the adhesive layer).

Embodiment 2

[0074] The patch obtained in the same manner as in Example 1 except that tolterodine acetate was not added was left at a temperature of 60° C. for 2 weeks to obtain the target patch.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A transdermal patch provided with a backing and a pressure-sensitive adhesive layer, wherein said pressure-sensitive adhesive layer includes at least one component selected from the group consisting of tolterodine acetate and salts thereof.

Description

technical field [0001] The invention relates to an adhesive agent and a method for enhancing the adhesion of the adhesive agent. Background technique [0002] Conventionally, from the viewpoint of suppressing side effects of oral administration or improving the quality of life of patients, patches for transdermal administration of active ingredients have been developed. Tolterodine (4-methyl-2-[(R)-3-(diisopropylamino)-1-phenylpropyl]phenol) and tolterodine derivatives of active ingredients such as Patches for their transdermal administration are disclosed. [0003] For example, Japanese Patent Application Laid-Open No. 2002-523446 (Patent Document 1) describes a transdermal patch for transdermally administering a salt, a prodrug, and a metabolite of tolterodine. In addition, Japanese Patent Application Laid-Open No. 2002-544222 (Patent Document 2) describes a compound containing an ammonium group-containing (meth)acrylate copolymer, at least one plasticizer, and tolterodi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/137A61K9/70A61K47/32A61P13/10
CPCA61K9/7061A61K31/137A61P13/10A61K9/7023
Inventor 筱田知宏内田尚志高田恭宪
Owner HISAMITSU PHARM CO INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap